Glenview Trust Co cut its holdings in Eli Lilly and Company (NYSE:LLY) by 4.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 84,257 shares of the company’s stock after selling 4,151 shares during the period. Glenview Trust Co’s holdings in Eli Lilly and were worth $6,934,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Acrospire Investment Management LLC lifted its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after acquiring an additional 200 shares during the last quarter. Point72 Asia Hong Kong Ltd lifted its stake in Eli Lilly and by 237.4% during the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new position in Eli Lilly and during the second quarter worth $148,000. Cornerstone Advisors Inc. lifted its stake in Eli Lilly and by 18.4% during the second quarter. Cornerstone Advisors Inc. now owns 2,013 shares of the company’s stock worth $166,000 after purchasing an additional 313 shares in the last quarter. Finally, Penserra Capital Management LLC lifted its stake in Eli Lilly and by 9.5% during the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares in the last quarter. Hedge funds and other institutional investors own 75.48% of the company’s stock.
Eli Lilly and Company (NYSE:LLY) opened at $82.49 on Wednesday. The company has a market capitalization of $91,236.74, a price-to-earnings ratio of 20.26, a P/E/G ratio of 1.83 and a beta of 0.34. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a twelve month low of $64.18 and a twelve month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. Eli Lilly and’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.88 earnings per share. equities analysts expect that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.
COPYRIGHT VIOLATION NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.themarketsdaily.com/2017/11/15/eli-lilly-and-company-lly-position-reduced-by-glenview-trust-co.html.
A number of research firms have commented on LLY. Berenberg Bank restated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research note on Wednesday, July 26th. BMO Capital Markets restated an “underperform” rating and set a $73.00 price target on shares of Eli Lilly and in a research note on Wednesday, July 26th. Jefferies Group LLC restated a “buy” rating and set a $89.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Leerink Swann upped their price target on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Hold” and an average target price of $89.76.
In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 772,003 shares of company stock worth $64,837,441. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.